Ascletis Pharma Executes HKD 1.22 Million Share Buyback; Cumulative Repurchases Reach 2.75 Million Shares under 2026 Mandate

Bulletin Express10-14

On 14 October 2026, Ascletis Pharma Inc. (Ascletis-B) disclosed the repurchase of 200,000 ordinary shares on the Hong Kong Stock Exchange, paying an aggregate HKD 1.22 million. The on-market purchases were executed within a price range of HKD 5.88 to HKD 6.72 per share, with a volume-weighted average cost of approximately HKD 6.11.

These shares, bought for cancellation, lift total buybacks under the mandate granted on 29 June 2026 to 2.75 million shares, equivalent to 0.26 % of the company’s issued share base on the mandate date. The current authorisation permits the repurchase of up to 106.14 million shares, leaving more than 103 million shares—over 97 % of the approved limit—still available.

Following the latest transaction, Ascletis’ issued share capital (excluding treasury shares) stands at 1.05 billion shares, while treasury shares total 5.78 million. Sixteen repurchase tranches executed between 30 June and 14 October 2026 remain pending cancellation.

Under Hong Kong listing rules, Ascletis is subject to a moratorium on new share issues or treasury-share sales until 13 November 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment